TIGIT and acute myeloid leukemia: NK92 cells engineered with a CD276-CAR (with CD276 found to be expressed at high levels in AML cell lines) and further edited with CRISPR/Cas9 knockout of the inhibitory receptors CBLB, NKG2A, and TIGIT showed enhanced in vitro cytotoxicity against various AML cell lines [63].